Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus

Bibliography

• HARTTER E, SVOBODA T, LUDVIK B et al.: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabeto/ogia (1991) 34:52–54.
   PubMed Web of Science ®Google Scholar
• NISHI M, SANKE T, SEINO S et al.: Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Ma. Endocrinol. (1989) 3:1775–1781.
   PubMed Web of Science ®Google Scholar
• MCLATCHIE LM, FRASER NJ, MAIN MJ et al.: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature (1998) 393:333–339.
   PubMed Web of Science ®Google Scholar
• MUFF R, BUHLMANN N, FISCHER JA et al.: An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology (1999) 140:2924–2927.
   PubMed Web of Science ®Google Scholar
• KODA JE, FINEMAN M, RINK TJ et al.: Amylin concentrations and glucose control. Lancet (1992) 339:1179–1180.
   PubMed Web of Science ®Google Scholar
• JOHNSON KH, O'BRIEN TD, BETSHOLTZ C et al.:Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl. J Med. (1989) 321:513–518.
   Google Scholar
• HOPPENER JW, AHREN B, LIPS CJ: Islet amyloid and Type 2 diabetes mellitus. N Engl. J Med. (2000) 343:411–419.
   PubMed Web of Science ®Google Scholar
• GOLDSBURY CS, COOPER GJ, GOLDIE KN et al.:Polymorphic fibrillar assembly of human amylin. I Struct. Biol. (1997) 119:17–27.
   Google Scholar
• WESTERMARK E ENGSTROM U, JOHNSON KH et al.: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Nati Acad. Sci. USA (1990) 87:5036–5040.
   PubMed Web of Science ®Google Scholar
• JAIKARAN ET, HIGHAM CE, SERPELL LC et al.: Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. MoL Bid. (2001) 308:515–525.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, VINE W, GEDULIN BR et al.: Preclinical Pharmacology of pramlintide in the rat: Comparison with human and rat amylin. Drug Dev. Res. (1996) 37:231–248.
   Web of Science ®Google Scholar
• COOPER GJ, WILLIS AC, CLARK A etal.: Purification and characterization of a peptide from amyloid-rich pancreases of Type 2 diabetic patients. Proc. Natl. Acad. Li. USA (1987) 84:8628–8632.
   Google Scholar
• WESTERMARK P, WERNSTED C, O'BRIEN TD et al.:Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am. J Pathol. (1987) 127:414–417.
   Google Scholar
• MOORE CX, COOPER GJ: Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. (1991) 179:1–9.
   PubMed Web of Science ®Google Scholar
• KODA JE, FINEMAN MS, KOLTERMAN OG et al.: 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes (1995) 44:238A
   Web of Science ®Google Scholar
• JUHL CB, PORKSEN N, STURIS J et al.: High-frequency oscillations in circulating amylin concentrations in healthy humans. Am. j Physiol. Endocrinol. Metab. (2000) 278:E484–E490.
   PubMed Web of Science ®Google Scholar
• NYHOLM B, FINEMAN MS, KODA JKet al.: Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus. Harm. Metall. Res. (1998) 30(4):206–212.
   Google Scholar
• KAUTZKY-WILLER A, THOMASETH K, PACINI G et al.: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia (1994) 37:188–194.
   PubMed Web of Science ®Google Scholar
• VINE W, SMITH P, LACHAPPELL R et al.: Nephrectomy decreases amylin and pramlintide clearance in rats. Harm. Metab Res. (1998) 30:514–517.
   PubMed Web of Science ®Google Scholar
• BEAUMONT K, KENNY MA, YOUNG AA et al.: High affinity amylin binding sites in rat brain. Ma. Pharmacol. (1993) 44:493–497.
   PubMed Web of Science ®Google Scholar
• SEXTON PM, PAXINOS G, KENNEY MA et al.: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience (1994) 62:553–557.
   PubMed Web of Science ®Google Scholar
• ROGERS RC, MCTIGUE DM, HERMANN GE: Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci. Biobehav. Rev. (1996) 20:57–66.
   PubMed Web of Science ®Google Scholar
• JODKA C, GREEN D, YOUNG A et al.:Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve. Diabetes (1996) 45:235A.
   Web of Science ®Google Scholar
• MARTINEZ A, KAPAS S, MILLER MJ et al.: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. Endocrinology (2000) 141(1):406–411.
   PubMed Web of Science ®Google Scholar
• TILAKARATNE N, CHRISTOPOULOS G, ZUMPE ET etal.: Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. Pharmacol Exp. Ther. (2000) 294(1):61–72.
   Google Scholar
• JUANEDA C, DUMONT Y, QUIRION R: The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sri. (2000) 21(11):432–438.
   PubMed Web of Science ®Google Scholar
• CHRISTOPOULOS G, PERRY KJ, MORFINS M et al.: Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mal Pharmacol (1999) 56(1):235–242.
   PubMed Web of Science ®Google Scholar
• ZUMPE ET, TILAKARATNE N, FRASER NJ et al: Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem. Biophys. Res. Commun. (2000) 267(1):368–372.
   PubMed Web of Science ®Google Scholar
• CASTILLO MJ, SCHEEN AJ, LEFEBVRE PJ: Amylin, Islet amyloid polypeptide: Biochemestry, Physiology, Pathophysiology. Diabete and Metabolism (Paris) (1995) 21:3–25.
   PubMed Web of Science ®Google Scholar
• COOPER GJ, LEIGHTON B, DIMITRIADIS GD et al: Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Nat] Acad. Sci. USA (1988) 85:7763–7766.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, GEDULIN B, WOLFE LOPEZ D et al: Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists. Am. j Physiol (1992) 263:E274–E281.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, MOTT DM, STONE K et al.: Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat. FEBS Lett. (1991) 281:149–151.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, WANG MW COOPER GJ: Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett. (1991) 291:101–104.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, CROCKER LB, WOLFE LOPEZ D et al: Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett. (1991) 287:203–205.
   PubMed Web of Science ®Google Scholar
• RODEN M, LIENER K, FURNSINN C et al.: Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver. Diabetologia (1992) 35:116–120.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, COOPER GJ, LEIGHTON B et al: Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes (1990) 39:260–265.
   PubMed Web of Science ®Google Scholar
• SOWA R, SANKE T, HIRAYAMA J et al:Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia (1990) 33:118–120.
   PubMed Web of Science ®Google Scholar
• FRONTONI S, CHOI SB, BANDUCH D etal.: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes (1991) 40:568–573.
   Google Scholar
• SILVESTRA RA, PEIDRO E, DEGANO P etal.: Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Rego] Pept. (1990) 31:23–31.
   Google Scholar
• CHUANG LM, WU HP, JOU TS et al: Inhibitory effect of islet amyloid polypeptide of glucose-induced proinsulin biosynthesis in rat insulinoma cells. Pancreas (1992) 7:472–476.
   PubMed Web of Science ®Google Scholar
• PETTERSSON M, AHREN B: Failure of islet amyloid polypeptide to inhibit basal and glucose-stimulated insulin secretion in model experiments in mice and rats. Acta Physiol Scam/. (1990) 138:389–394.
   PubMedGoogle Scholar
• WANG ZL, BENNET WM, GHATEI MA et al.: Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes (1993) 42:330–335.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, CARLO P, RINK TJ et al: 8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats. Mal Cell Endocfirrol. (1992) 84:R1–R5.
   PubMed Web of Science ®Google Scholar
• GEDULIN BR, RINK TJ, YOUNG AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism (1997) 46:67–70.
   PubMed Web of Science ®Google Scholar
• GEDULIN B, JODKA C, GREEN D et al.: Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like peptide-1(7-36)-amide (GLP-1). Diabetologia (1996) 39:154A.
   Web of Science ®Google Scholar
• SILVESTRE RA, RODRIGUEZ-GALLARDO J, JODKA C et al: Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. Physiol Endocfirrol. Metab. (2001) 280:E443–E449.
   PubMed Web of Science ®Google Scholar
• MACDONALD IA: Amylin and the gastrointestinal tract. Diabetic Medicine (1997) 14:S24–S28.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, GEDULIN BR, RINK T: Dose-response for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism (1996) 45:1–3.
   PubMed Web of Science ®Google Scholar
• YOUNG AA, GEDULIN B, VINE W et al.: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia (1995) 38:642–648.
   PubMed Web of Science ®Google Scholar
• GEDULIN BR, YOUNG AA: Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes (1998) 47:93–97.
   PubMed Web of Science ®Google Scholar
• GEDULIN B, LAWLER R, JODKA C et al.: Amylin inhibits pentagastrin-stimulated gastric acid secretion: Comparison with glucagon-like peptide-1 and exendin-4. Diabetes (1997) 40:188A.
   Google Scholar
• GEDULIN BR, JODKA C, LAWLER R et al.: Amylin inhibits lipase and amylase secretion from the exocrine pancreas in rats. Diabetes (1998) 47:A280.
   Web of Science ®Google Scholar
• MORLEY JE, FLOOD JF, FARR SA et al: Effects of amylin on appetite regulation and memory. Can. I Physic] Pharmacol (1995) 73:1042–1046.
   PubMed Web of Science ®Google Scholar
• LUTZ TA, DEL PRETE E, SCARRER E: Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav. (1994) 55:891–895.
   PubMed Web of Science ®Google Scholar
• LUTZ TA, DEL PRETE E, SCARRER E: Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides (1995) 16:457–462.
   PubMed Web of Science ®Google Scholar
• DEVINE E, YOUNG AA: Weight gain in male and female mice with amylin gene knockout. Diabetes (1998) 47:A317.
   Web of Science ®Google Scholar
• BRETHERTON-WATT D, GILBEY SG, GHATEI MA et al: Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia (1990) 33:115–117.
   PubMed Web of Science ®Google Scholar
• BRETHERTON-WATT D, GILBEY SG, GHATEI MA et al: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. I Chu. Endocrirrol Metab (1992) 74:1032–1035.
   PubMed Web of Science ®Google Scholar
• WILDING JP, KHANDAN NIA N, BENNET WM et al: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia (1994) 37:166–169.
   PubMed Web of Science ®Google Scholar
• ZIERATH JR, GALUSKA D, ENGSTROM A etal.: Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips. Diabetologia (1992) 35:26–31.
   Google Scholar
• COLBURN WA, GOTTLIEB AB, KODA J et al: Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. j Chi]. Pharmacol (1996) 36:13–24.
   Google Scholar
• ATKINSON MA, MACLAREN NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl. J Med. (1994) 331:1428–1436.
   PubMed Web of Science ®Google Scholar
• PORTE DJ: Banting lecture 1990. Beta-cells in Type II diabetes mellitus. Diabetes (1991) 40:166–180.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Postprandial Blood Glucose. Diabetes Care (2001) 24(4): 775–778.
   PubMed Web of Science ®Google Scholar
• UNGER RH, ORCI L: Glucagon and the A cell: physiology and pathophysiology. N Engl. J Med. (1981) 304:1575–1580.
   PubMed Web of Science ®Google Scholar
• PEHLING G, TESSARI P, GERICH JE et al.: Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J. Chi]. Invest (1984) 74:985–991.
   Google Scholar
• DINNEEN S, GERICH J, RIZZA R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl. Med. (1992) 327:707–713.
   PubMed Web of Science ®Google Scholar
• SHERWIN RS, FISHER M, HENDLER R et al.: Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl. j Med. (1976) 294:455–461.
   PubMed Web of Science ®Google Scholar
• SCHVARCZ E, PALMER M, AMAN J et al.: Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology (1997) 113:60–66.
   PubMed Web of Science ®Google Scholar
• KONG MF, KING P, MACDONALD IA et al: Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia (1998) 41:474–481.
   PubMed Web of Science ®Google Scholar
• WAHREN J, FELING P, HAGENFELDT L: Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. j Chi]. Invest (1976) 57:987–999.
   PubMed Web of Science ®Google Scholar
• FRANK JW, SASLOW SB, CAMILLERI M et al.: Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type II diabetes mellitus. Gastroenterology (1995) 109:755–765.
   PubMed Web of Science ®Google Scholar
• RAYNER CK, SAMSOM M, JONES KL et al.: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care (2001) 24:371–381.
   PubMed Web of Science ®Google Scholar
• GALE EA, CLARK A: A drug on the market? Lancet (2000) 355:61–63.
   PubMed Web of Science ®Google Scholar
• KOLTERMAN OG, GOTLIEB A: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care (1995) 18:1179–1182.
   PubMed Web of Science ®Google Scholar
• THOMPSON RG, GOTTLIEB A, ORGAN K etal.: Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet. Med. (1997) 14:547–555.
   Google Scholar
• KONG MF, KING P, MACDONALD IA et al: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia (1997) 40:82–88.
   PubMed Web of Science ®Google Scholar
• NYHOLM B, MOLLER N, GRAVHOLT CH et al.: Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. j CM]. Endocnnol Metab. (1996) 81:1083–1089.
   PubMed Web of Science ®Google Scholar
• KOLTERMAN OG, SCHWARTZ S, CORDER C et al: Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia (1996) 39:492–499.
   PubMed Web of Science ®Google Scholar
• THOMPSON RG, PETERSON J, GOTTLIEB A etal.: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes (1997) 46:632–636.
   Google Scholar
• THOMPSON RG, PEARSON L, KOLTERMAN OG: Effects of 4 week's administration of pramlintide, a human amylin analogue, on glycemic control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia (1997) 40:1278–1285.
   PubMed Web of Science ®Google Scholar
• NYHOLM B, ORSKOV L, HOVE KY eta].: The amylin analogue Pramlintide Improves Glycemic Control and Reduces Postprandial Glucagon Concentrations in Patients with Type 1 Diabetes Mellitus. Metabolism (1999) 48(7):935–941.
   Google Scholar
• THOMPSON RG, PEARSON L, SCHOENFELD SL etal.: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with *type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care (1998) 21:987–993.
   Google Scholar
• ORSKOV L, NYHOLM B, HOVE KY et al.: Effects of the amylin analogue pramlintide on hepatic glucogen responses and intermediary metabolism in *type 1 diabetic subjects. Diabetic Medicine (1999) 16: 867–874.
   PubMed Web of Science ®Google Scholar
• FINEMAN M, KODA J, KOLTERMAN 0: Subcutaneous administration of a human amylin analogue suppresses postprandial glucagon concentrations in Type 1 diabetic patients. Diabetes (1998) 47:A89.
   Web of Science ®Google Scholar
• LEAMING R, JOHNSON A, HOOK G et al.: Amylin modulates insulin secretion in humans. Studies with an amylin agonist. Diabetologia (1995) 38:A113.
   Google Scholar
• GUTNIAK M, SVARTBERG J, PETRELLA E et al.: Effects of Pramlintide (Amylin Agonist) in Type 1 Diabetes are not mediated by GLP-1 (7-36) amide. Diabetes (2000) 49: A109.
   Web of Science ®Google Scholar
• FINEMAN M, KOLTERMAN 0, THOMPSON R et al: The Human Amylin Analogue Pramlintide Inhibited Glucagon Secretion in Type 1 Diabetic Subjects. Diabetes (1997) 46:30A.
   Web of Science ®Google Scholar
• FRADKIN J, SHAMOON H, FELIG P et al.: Evidence for an important role of changes in rather than absolute concentrations of glucagon in the regulation of glucose production in humans. I Chi]. Endocnnol Metab. (1980) 50:698–703.
   PubMed Web of Science ®Google Scholar
• DINNEEN S, ALZAID A, TURK D et al: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia (1995) 38:337–343.
   PubMed Web of Science ®Google Scholar
• BARON AD, SCHAEFFER L, SHRAGG P etal.: Role of hyperglucagonamia in maintenance of increased rates of hepatic glucose output in Type II diabetes mellitus. Diabetes (1987) 36:274–283.
   Google Scholar
• ROSENSTOCK J, WHITEHOUSE F, SCHOENFELD S et al: Effect of Pramlintide on metabolic control and safety profile in people with Type 1 diabetes. Diabetes (1998) 47:A88.
   Web of Science ®Google Scholar
• RATNER R, LEVETAN C, SCHOENFELD S et al.: Pramlintide therapy in the treatment of insulin-requiring Type 2 diabetes: Results of a 1-year placebo-controlled trial. Diabetes (1998) 47:A88.
   Web of Science ®Google Scholar
• FINEMAN M, GOTTLIEB A, BAHNER A et al.: Pramlintide therapy in addition to insulin in type 1 diabetes: Effects on metabolic control after 6 months. Diabetologia (1999) 42:A232.
   Google Scholar
• GOTTLIEB A, FINEMAN M, BAHNER A et al.: Pramlintide therapy in addition to insulin in type 2 diabetes: Effects on metabolic control after 6 months. Diabetologia (1999) 42:A232.
   Google Scholar
• GOTTLIEB A, VELTE M, FINEMAN M etal.: Pramlintide as an adjunct to insulin theraphy improves glycemic and weight control in people with Type 1 diabetes during treatment for 52 weeks. Diabetes (2000) 49:A109.
   Google Scholar
• FINEMAN M, GOTTLIEB A, SKARE S etal.: Pramlintide as an adjunct to insulin theraphy improves glycemic and weight control in people with Type 2 diabetes during treatment for 52 weeks. Diabetes (2000) 49:A106.
   Google Scholar
• KOLTERMAN OG, BAHNER A, GOTTLIEB A et al.: Pramlintide (human amylin analogue) as an adjunct to insulin therapy in patients with Type 1 diabetes improves glycemic control over 2 years. Diabetes (1999) 48:A104.
   Web of Science ®Google Scholar
• THE DIABETES CONTROL AND COMPLICATION TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. j Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar